Beacon Pharmaceuticals (BEACONPHAR) Stock Overview
Engages in the producing and promoting of pharmaceuticals finished formulations, lifesaving intravenous fluids, active pharmaceutical ingredients, bio-tech, and genetic engineering products in Bangladesh and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
BEACONPHAR Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Beacon Pharmaceuticals PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ৳112.10 |
| 52 Week High | ৳147.50 |
| 52 Week Low | ৳96.00 |
| Beta | -0.38 |
| 1 Month Change | 6.36% |
| 3 Month Change | 14.27% |
| 1 Year Change | 0.45% |
| 3 Year Change | -54.24% |
| 5 Year Change | -26.40% |
| Change since IPO | 29.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| BEACONPHAR | BD Pharmaceuticals | BD Market | |
|---|---|---|---|
| 7D | 0.8% | 1.4% | 0.9% |
| 1Y | 0.4% | 13.7% | 7.1% |
Return vs Industry: BEACONPHAR underperformed the BD Pharmaceuticals industry which returned 13.7% over the past year.
Return vs Market: BEACONPHAR underperformed the BD Market which returned 7.1% over the past year.
Price Volatility
| BEACONPHAR volatility | |
|---|---|
| BEACONPHAR Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 4.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in BD Market | 7.1% |
| 10% least volatile stocks in BD Market | 2.8% |
Stable Share Price: BEACONPHAR has not had significant price volatility in the past 3 months compared to the BD market.
Volatility Over Time: BEACONPHAR's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 4,771 | Ulfat Karim | www.beaconmedicare.com.bd |
Beacon Pharmaceuticals PLC engages in the producing and promoting of pharmaceuticals finished formulations, lifesaving intravenous fluids, active pharmaceutical ingredients, bio-tech, and genetic engineering products in Bangladesh and internationally. The company offers general, oncology, biotech, and chronic care products. It also provides products in various therapeutic categories such as oncology, hematology, anti-cancer, hepatology, nephrology, antibiotics, analgesics, anti-diabetics, respiratory, cardiovascular, dermatology, gastrointestinal, infectious diseases, immunology, rheumatology, muscle relaxants, antihistamines, anti-coagulants, protein supplements, pediatrics, NSAIDs, nutritional supplements, and others.
Beacon Pharmaceuticals PLC Fundamentals Summary
| BEACONPHAR fundamental statistics | |
|---|---|
| Market cap | ৳25.90b |
| Earnings (TTM) | ৳1.46b |
| Revenue (TTM) | ৳15.57b |
Is BEACONPHAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BEACONPHAR income statement (TTM) | |
|---|---|
| Revenue | ৳15.57b |
| Cost of Revenue | ৳7.48b |
| Gross Profit | ৳8.09b |
| Other Expenses | ৳6.63b |
| Earnings | ৳1.46b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.31 |
| Gross Margin | 51.95% |
| Net Profit Margin | 9.36% |
| Debt/Equity Ratio | 120.1% |
How did BEACONPHAR perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/10 23:00 |
| End of Day Share Price | 2026/07/09 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Beacon Pharmaceuticals PLC is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.